| Active, not recruiting | 1/2 | 46 | Canada, US | Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal | St. Jude Children's Research Hospital, Pfizer, Ipsen | Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma | 12/25 | 12/25 | | |
NCT06023641: Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease |
|
|
| Recruiting | 1/2 | 100 | US | Vincristine, Oncovin, Dactinomycin, (actinomycin-D), Cyclophosphamide, Cytoxan®., Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, (Onivyde®), Vinorelbine, Navelbine, Temozolomide, Temodar, Filgrastim, peg-filgrastim, Neupogen | St. Jude Children's Research Hospital | Rhabdomyosarcoma | 10/34 | 10/37 | | |